title: An open trial of low dose buprenorphine in treating methadone withdrawal.
abstract: Buprenorphine (BPN) is a prescription analgesic with mixed opioid agonist and antagonist properties. This pilot study conducted detailed case studies with 15 methadone dependent patients. The study sought to determine whether repeated low doses (0.15 to 0.3 mg) of sublingual BPN would relieve opioid withdrawal symptoms. Subjects developed mild to moderate withdrawal symptoms within 26 to 31 hours of methadone discontinuation. Once in withdrawal, the subjects received 0.15 mg of BPN sublingually. A second dose of 0.15 mg was administered in an hour, and a 0.30 mg dose in 2 hours, if the subject obtained no relief of withdrawal symptoms. In 6 subjects a low dose of 0.15 to 0.30 mg sublingual BPN resulted in the disappearance of subjective and objective withdrawal symptoms within 10 minutes to 2.5 hours. Four others had brief, partial relief of symptoms. Five subjects failed to experience any relief of withdrawal symptoms after a total of 0.6 mg BPN administered over 3 hours. One nonresponder suffered what appeared to be a severe precipitated withdrawal reaction similar to that which can be produced in addicts by a naloxone challenge. The 4 Caucasian responders required 1 to 2 hours to respond to BPN, whereas the 2 African-American responders required only 10 to 20 minutes. Low (analgesic) doses of BPN were sufficient to treat all methadone withdrawal symptoms in 6 of 15 subjects. There may be ethnic differences in response to BPN. Low dose BPN may play a role in carefully monitored heroin detoxification treatment.
authors.affiliation: Substance Abuse Programs, VA Medical Center, San Francisco, CA 94121.
authors.forename: P
authors.initials: P
authors.lastname: Banys
authors.forename: H W
authors.initials: HW
authors.lastname: Clark
authors.forename: D J
authors.initials: DJ
authors.lastname: Tusel
authors.forename: K
authors.initials: K
authors.lastname: Sees
authors.forename: P
authors.initials: P
authors.lastname: Stewart
authors.forename: L
authors.initials: L
authors.lastname: Mongan
authors.forename: K
authors.initials: K
authors.lastname: Delucchi
authors.forename: E
authors.initials: E
authors.lastname: Callaway
mesh_terms: D000328:Adult; D000368:Aged; D003866:Depressive Disorder / Q000139:chemically induced / Q000523:psychology / Q000534:rehabilitation; D004305:Dose-Response Relationship, Drug; D006556:Heroin Dependence / Q000523:psychology / Q000534:rehabilitation; D006787:Hospitals, Veterans; D006801:Humans; D008691:Methadone / Q000009:adverse effects*; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D009293:Opioid-Related Disorders / Q000523:psychology / Q000534:rehabilitation*; D017060:Patient Satisfaction; D010555:Personality Inventory; D013375:Substance Withdrawal Syndrome / Q000523:psychology / Q000534:rehabilitation*
chemical_list: D008691:Methadone